Therapeutic dendritic-cell vaccine for simian AIDS
- PMID: 12496959
- DOI: 10.1038/nm806
Therapeutic dendritic-cell vaccine for simian AIDS
Abstract
An effective immune response against human immunodeficiency virus or simian immunodeficiency virus (SIV) is critical in achieving control of viral replication. Here, we show in SIV-infected rhesus monkeys that an effective and durable SIV-specific cellular and humoral immunity is elicited by a vaccination with chemically inactivated SIV-pulsed dendritic cells. After three immunizations made at two-week intervals, the animals exhibited a 50-fold decrease of SIV DNA and a 1,000-fold decrease of SIV RNA in peripheral blood. Such reduced viral load levels were maintained over the remaining 34 weeks of the study. Molecular and cellular analyses of axillary and inguinal node lymphocytes of vaccinated monkeys revealed a correlation between decreased SIV DNA and RNA levels and increased SIV-specific T-cell responses. Neutralizing antibody responses were augmented and remained elevated. Inactivated whole virus-pulsed dendritic cell vaccines are promising means to control diseases caused by immuno- deficiency viruses.
Comment in
-
Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine.Nat Med. 2003 Jan;9(1):13-4. doi: 10.1038/nm0103-13. Nat Med. 2003. PMID: 12514710 No abstract available.
Similar articles
-
Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).Virology. 2001 Jan 5;279(1):241-56. doi: 10.1006/viro.2000.0695. Virology. 2001. PMID: 11145906
-
A dendritic cell-based vaccine for treating HIV infection: background and preliminary results.J Intern Med. 2007 Feb;261(2):123-31. doi: 10.1111/j.1365-2796.2006.01738.x. J Intern Med. 2007. PMID: 17241177
-
Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.Vaccine. 2006 Mar 10;24(11):1811-20. doi: 10.1016/j.vaccine.2005.10.026. Epub 2005 Oct 25. Vaccine. 2006. PMID: 16274888
-
Immunity in natural SIV infections.J Intern Med. 2009 Jan;265(1):97-109. doi: 10.1111/j.1365-2796.2008.02049.x. J Intern Med. 2009. PMID: 19093963 Review.
-
Cytotoxic T lymphocytes specific for the simian immunodeficiency virus.Immunol Rev. 1999 Aug;170:127-34. doi: 10.1111/j.1600-065x.1999.tb01334.x. Immunol Rev. 1999. PMID: 10566147 Review.
Cited by
-
Regulatory T cells in HIV infection: can immunotherapy regulate the regulator?Clin Dev Immunol. 2012;2012:908314. doi: 10.1155/2012/908314. Epub 2012 Oct 15. Clin Dev Immunol. 2012. PMID: 23251223 Free PMC article. Review.
-
Study on biological characters of SGC7901 gastric cancer cell-dendritic cell fusion vaccines.World J Gastroenterol. 2006 Jun 7;12(21):3438-41. doi: 10.3748/wjg.v12.i21.3438. World J Gastroenterol. 2006. PMID: 16733866 Free PMC article.
-
Poly(ethylene glycol)-Lipid-Conjugated Antibodies Enhance Dendritic Cell Phagocytosis of Apoptotic Cancer Cells.Pharmaceuticals (Basel). 2012 Apr 26;5(5):405-16. doi: 10.3390/ph5050405. Pharmaceuticals (Basel). 2012. PMID: 24281554 Free PMC article.
-
Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study.Vaccine. 2011 Feb 11;29(8):1617-23. doi: 10.1016/j.vaccine.2010.12.066. Epub 2011 Jan 4. Vaccine. 2011. PMID: 21211581 Free PMC article. Clinical Trial.
-
A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.PLoS One. 2010 Sep 21;5(9):e12891. doi: 10.1371/journal.pone.0012891. PLoS One. 2010. PMID: 20877632 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources